Literature DB >> 9213246

Wild-type p53 gene-induced morphological changes and growth suppression in hepatoma cells.

S Terai1, T Noma, T Kimura, A Nakazawa, F Kurokawa, K Okita.   

Abstract

The human hepatocellular carcinoma (HCC) cell line, HLF, expresses only mutant-type p53 (mt-p53), which has an amino acid substitution at the 244th residue from glycine to alanine. HLF cells were transfected with wild-type p53 (wt-p53) cDNA construct pC53-SN3, mt-p53 cDNA construct pC53-SCX [which differs by a single nucleotide, resulting in alanine instead of valine at the 143rd residue in p53 (p53-143)], or pCMV-Neo-Bam, as a control, by a liposome method. After G418 selection, three wt-p53 stable transformants (WT), four mt-p53 transformants (MT), and three control vector transformants (VT) were obtained. We analyzed the cell growth and morphological changes of these transformants under different culture conditions [fetal calf serum (FCS), 10%, 1%, and 0%]. Whereas no difference from control in the growth rate and morphology was observed under the 10% FCS conditions, serum starvation induced remarkable phenotypical changes in all three WTs, but not in the other transformant. Corresponding to these phenotypical changes, the transcriptional activity of wt-p53 was increased more than nine fold. These results indicated that serum starvation would induce wt-p53 biological function, which is tightly linked to morphological changes and growth suppression. To induce these changes, the introduction of the wt-p53 gene itself was not sufficient, and additional triggering, i.e., serum starvation, was indispensable.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9213246     DOI: 10.1007/bf02934489

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  55 in total

1.  Genetic mechanisms of tumor suppression by the human p53 gene.

Authors:  P L Chen; Y M Chen; R Bookstein; W H Lee
Journal:  Science       Date:  1990-12-14       Impact factor: 47.728

2.  p53 domains: identification and characterization of two autonomous DNA-binding regions.

Authors:  Y Wang; M Reed; P Wang; J E Stenger; G Mayr; M E Anderson; J F Schwedes; P Tegtmeyer
Journal:  Genes Dev       Date:  1993-12       Impact factor: 11.361

3.  p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis.

Authors:  S J Baker; A C Preisinger; J M Jessup; C Paraskeva; S Markowitz; J K Willson; S Hamilton; B Vogelstein
Journal:  Cancer Res       Date:  1990-12-01       Impact factor: 12.701

Review 4.  The p53 tumour suppressor gene.

Authors:  A J Levine; J Momand; C A Finlay
Journal:  Nature       Date:  1991-06-06       Impact factor: 49.962

5.  Tetrazolium-based assays for cellular viability: a critical examination of selected parameters affecting formazan production.

Authors:  D T Vistica; P Skehan; D Scudiero; A Monks; A Pittman; M R Boyd
Journal:  Cancer Res       Date:  1991-05-15       Impact factor: 12.701

6.  Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors.

Authors:  U M Moll; M LaQuaglia; J Bénard; G Riou
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-09       Impact factor: 11.205

7.  Expression of oncogenes and tumor suppressor genes in human hepatocellular carcinoma and hepatoblastoma cell lines.

Authors:  M Farshid; E Tabor
Journal:  J Med Virol       Date:  1992-12       Impact factor: 2.327

8.  A retroviral wild-type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis.

Authors:  T Fujiwara; E A Grimm; T Mukhopadhyay; D W Cai; L B Owen-Schaub; J A Roth
Journal:  Cancer Res       Date:  1993-09-15       Impact factor: 12.701

Review 9.  A comparison of the biological activities of wild-type and mutant p53.

Authors:  G P Zambetti; A J Levine
Journal:  FASEB J       Date:  1993-07       Impact factor: 5.191

10.  Hemi- or homozygosity: a requirement for some but not other p53 mutant proteins to accumulate and exert a pathogenetic effect.

Authors:  K Bhatia; W Goldschmidts; M Gutierrez; G Gaidano; R Dalla-Favera; I Magrath
Journal:  FASEB J       Date:  1993-07       Impact factor: 5.191

View more
  1 in total

1.  Sorafenib suppresses the cell cycle and induces the apoptosis of hepatocellular carcinoma cell lines in serum-free media.

Authors:  Minoru Tomizawa; Fuminobu Shinozaki; Takao Sugiyama; Shigenori Yamamoto; Makoto Sueishi; Takanobu Yoshida
Journal:  Exp Ther Med       Date:  2010-07-21       Impact factor: 2.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.